{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:57:56Z","timestamp":1792684676625,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tjpad.2026.100599","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:28:03Z","timestamp":1779182883000},"page":"100599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biomarkers in preclinical and early Alzheimer\u2019s disease in China: a scoping review"],"prefix":"10.1016","volume":"13","author":[{"given":"Guoping","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar Anil","family":"Chandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7686-0547","authenticated-orcid":false,"given":"Jintai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100599_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0002","doi-asserted-by":"crossref","first-page":"e1534","DOI":"10.1016\/S2214-109X(24)00264-X","article-title":"The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories","volume":"12","author":"Chen","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.tjpad.2026.100599_bib0003","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.tjpad.2026.100599_bib0004","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0005","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0006","first-page":"3292","article-title":"Aging Biomarker Consortium, Writing Group for the Chinese Guideline for Clinical application of fluid biomarkers for Alzheimer\u2032s Disease. [Chinese guideline for clinical application of fluid biomarkers for Alzheimer\u2019s disease(2024 edition)]","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.tjpad.2026.100599_bib0007","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0008","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100599_bib0009","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.scib.2023.07.009","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: a multicenter-based cross-sectional and longitudinal study in China","volume":"68","author":"Gao","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.tjpad.2026.100599_bib0010","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/alz.12700","article-title":"A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer\u2019s dementia: china Aging and Neurodegenerative Initiative (CANDI) study","volume":"19","author":"Gao","year":"2023","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0011","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","article-title":"Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts","volume":"14","author":"Cai","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2026.100599_bib0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/alz.12166","article-title":"Blood neuro-exosomal synaptic proteins predict Alzheimer\u2019s disease at the asymptomatic stage","volume":"17","author":"Jia","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-022-00977-x","article-title":"Combination of gut microbiota and plasma amyloid-\u03b2 as a potential index for identifying preclinical Alzheimer\u2019s disease: a cross-sectional analysis from the SILCODE study","volume":"14","author":"Sheng","year":"2022","journal-title":"Alzheimer Res Ther"},{"key":"10.1016\/j.tjpad.2026.100599_bib0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","article-title":"Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression","volume":"69","author":"Shen","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.tjpad.2026.100599_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjpad.2026.100599_bib0016","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.tjpad.2026.100599_bib0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0018","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0021","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13643-020-01324-7","article-title":"Machine learning for screening prioritization in systematic reviews: comparative performance of Abstrackr and EPPI-Reviewer","volume":"9","author":"Tsou","year":"2020","journal-title":"Syst Rev"},{"key":"10.1016\/j.tjpad.2026.100599_bib0023","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0024","article-title":"Impaired cerebral blood flow in type 2 diabetes mellitus \u2013 A comparative study with subjective cognitive decline, vascular dementia and Alzheimer\u2019s disease subjects","volume":"27","author":"Chau","year":"2020","journal-title":"NeuroImage: Clin"},{"key":"10.1016\/j.tjpad.2026.100599_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112535","article-title":"Tau pathology mediated the plasma biomarkers and cognitive function in patients with mild cognitive impairment","volume":"195","author":"Zhao","year":"2024","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0026","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2021.12.015","article-title":"Exosomal MicroRNA-based predictive model for preclinical Alzheimer\u2019s disease: a multicenter study","volume":"92","author":"Jia","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100599_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.605734","article-title":"Radiomics analysis of Magnetic resonance imaging facilitates the identification of preclinical Alzheimer\u2019s disease: an exploratory study","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14536","article-title":"Plasma p-tau217 and p-tau217\/A\u03b21-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: insights for research and clinical practice","volume":"21","author":"Zhong","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0029","article-title":"Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0030","first-page":"1520","article-title":"[Diagnostic value of Phosphorylated tau217 and other plasma biomarkers for cognitive dysfunction in the populations of Deyang City, Sichuan Province, China]","volume":"55","author":"Lai","year":"2024","journal-title":"Sichuan Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.tjpad.2026.100599_bib0031","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease in down syndrome: a systematic review and meta-analysis","volume":"21","author":"Zhou","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0032","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2026.100599_bib0033","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/alz.13449","article-title":"The Alzheimer\u2019s disease neuroimaging initiative in the era of Alzheimer\u2019s disease treatment: a review of ADNI studies from 2021 to 2022","volume":"20","author":"Veitch","year":"2024","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14321","article-title":"Overview of Alzheimer\u2019s disease neuroimaging initiative and future clinical trials","volume":"21","author":"Weiner","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0035","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0036","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0037","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trci.2018.11.004","article-title":"FDA position statement \u201cearly Alzheimer\u2019s disease: developing drugs for treatment, guidance for industry","volume":"5","author":"Sabbagh","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2026.100599_bib0039","first-page":"1631","article-title":"Lecanemab in early Alzheimer\u2019s Disease","volume":"388","author":"Brenman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2026.100599_bib0040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100599_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100092","article-title":"Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer\u02bcs disease in a Chinese cohort","volume":"12","author":"Li","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100599_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0043","unstructured":"National Medical Products Administration. 2024. Available at: https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9YzMyYTUxZWM2OGVlMzk4ZTQyYzkxYmM5MjM3ODNjYzUmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTgzY2I2NmZlNjkwMjg1 (accessed March 12, 2026)."},{"key":"10.1016\/j.tjpad.2026.100599_bib0044","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2025.3217","article-title":"Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease","volume":"82","author":"Salvad\u00f3","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100092","article-title":"Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer\u02bcs disease in a Chinese cohort","volume":"12","author":"Li","year":"2025","journal-title":"J Prev Alzheimer Dis"},{"key":"10.1016\/j.tjpad.2026.100599_bib0049","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2026.100599_bib0050","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/acn3.51652","article-title":"A population-based meta-analysis of circulating GFAP for cognition and dementia risk","volume":"9","author":"Gonzales","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0048","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40001-023-01631-4","article-title":"Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)","volume":"29","author":"Zheng","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.tjpad.2026.100599_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-01511-3","article-title":"Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit","volume":"15","author":"\u00c1lvarez-S\u00e1nchez","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2026.100599_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70066","article-title":"Plasma phosphorylated Tau 217 as a discriminative biomarker for cerebral amyloid angiopathy","volume":"32","author":"Hsieh","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0053","article-title":"Cross-cultural validation of plasma p-tau217 and p-tau181 as precision biomarkers for amyloid PET positivity: an East Asian study in Taiwan and Korea","volume":"21","author":"Lin","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0054","unstructured":"US Food and Drug Administration. 2025. FDA clears first blood test used in diagnosing Alzheimer\u2019s disease. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease."},{"key":"10.1016\/j.tjpad.2026.100599_bib0055","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/alz.13676","article-title":"A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer\u2019s disease across ethnic groups","volume":"20","author":"Jiang","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100599_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.605734","article-title":"Radiomics analysis of Magnetic resonance imaging facilitates the identification of preclinical Alzheimer\u2019s disease: an exploratory study","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.tjpad.2026.100599_bib0057","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/cercor\/bhac084","article-title":"Identification of subjective cognitive decline due to Alzheimer\u2019s disease using multimodal MRI combining with machine learning","volume":"33","author":"Lin","year":"2023","journal-title":"Cereb Cortex (N Y NY 2F: 1991)"},{"key":"10.1016\/j.tjpad.2026.100599_bib0058","article-title":"Alzheimer\u2019s disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling","volume":"5","author":"Tao","year":"2024","journal-title":"Innov (Camb)"},{"key":"10.1016\/j.tjpad.2026.100599_bib0059","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3233\/JAD-230182","article-title":"Early diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease using a composite of MemTrax and blood biomarkers","volume":"94","author":"Chen","year":"2023","journal-title":"J Alzheimer Dis 2F: JAD"},{"key":"10.1016\/j.tjpad.2026.100599_bib0060","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1038\/s41467-022-31037-5","article-title":"Multimodal deep learning for Alzheimer\u2019s disease dementia assessment","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2026.100599_bib0061","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1002\/alz.13412","article-title":"Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: a systematic review","volume":"19","author":"Borchert","year":"2023","journal-title":"Alzheimer Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:03:54Z","timestamp":1783922634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072600124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S227458072600124X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100599","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in preclinical and early Alzheimer\u2019s disease in China: a scoping review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100599"}}